FeLV, FIV Treatment Aid Receives Conditional License Renewal

Product approved as treatment aid for cats infected with the viruses.

Posted Jan. 2, 2009, 3 a.m. EST

Printer Friendly

San Diego-based biotechnology company T-Cyte Therapeutics Inc. has received a conditional license renewal for its Lymphocyte T-Cell Immunomodulator (LTCI).

The product, which is injected under the skin, is approved as a treatment aid for cats infected with feline leukemia virus (FeLV) and immunodeficiency virus (FIV) and the associated symptoms of lymphopenia, opportunistic infection, anemia, granulocytopenia or thrombocytopenia.

FeLV and FIV are two prevalent retroviruses in cats. Infections with the viruses often result in immune dysfunction and increased risk of opportunistic infections. FeLV can be associated with certain forms of feline cancer, including leukemia and lymphoma.

LTCI is distributed by Imulan BioTherapeutics LLC of Prescott, Ariz.

Printer Friendly

 Give us your opinion on
FeLV, FIV Treatment Aid Receives Conditional License Renewal

Submit a Comment   Join Club
Earn 1,000 points! What's this?
Reader Comments

Shannon    Danville, IL

1/3/2009 7:19:03 PM

I'm glad to hear of this!! I had a cat that had FIV.

Cathy    Hubbard, OH

1/2/2009 7:33:07 AM

Interesting. It says renewal??? I have never heard of this before. Have they been treating cats with the virus successfully up to now? I know of some cats that have been put down because of this. Are they still contagious to other cats? Thanks for the information.

Stacey    Leduc, AB

1/2/2009 6:19:49 AM

Great news!

lia    des moines, IA

1/2/2009 5:03:38 AM


View Current Comments

Top Products